↓ Skip to main content

Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection

Overview of attention for article published in OncoTargets and therapy, September 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (73rd percentile)
  • High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

patent
2 patents
wikipedia
1 Wikipedia page

Citations

dimensions_citation
28 Dimensions

Readers on

mendeley
49 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection
Published in
OncoTargets and therapy, September 2016
DOI 10.2147/ott.s97397
Pubmed ID
Authors

Steven S Yu, David I Quinn, Tanya B Dorff

Timeline

Login to access the full chart related to this output.

If you don’t have an account, click here to discover Explorer

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 49 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 6 12%
Researcher 6 12%
Student > Master 5 10%
Other 4 8%
Student > Ph. D. Student 4 8%
Other 7 14%
Unknown 17 35%
Readers by discipline Count As %
Medicine and Dentistry 12 24%
Biochemistry, Genetics and Molecular Biology 8 16%
Pharmacology, Toxicology and Pharmaceutical Science 3 6%
Agricultural and Biological Sciences 3 6%
Chemistry 2 4%
Other 3 6%
Unknown 18 37%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 June 2024.
All research outputs
#5,446,994
of 25,374,647 outputs
Outputs from OncoTargets and therapy
#278
of 3,016 outputs
Outputs of similar age
#85,581
of 348,376 outputs
Outputs of similar age from OncoTargets and therapy
#9
of 86 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 348,376 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 86 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.